肿瘤坏死因子相关凋亡诱导配体在消化系统肿瘤治疗中的研究进展  

Research progress of TRAIL in the treatment of digestive cancer

作　　者：李大欢 许良璧 刘雪影 唐山 邓超男 LI Da-huan;XU Liang-bi;LIU Xue-ying;TANG Shan;DENG Chao-nan(Department of Internal Medicine,Clinic School,Guizhou Medical University,Guiyang 550000,China;Department of Pathology,Clinic School,Guizhou Medical University,Guiyang 550000,China)

机构地区：[1]贵州医科大学临床医学院内科教研室,550000 [2]贵州医科大学临床医学院病理教研室,550000

出　　处：《天津医药》2021年第11期1228-1232,共5页Tianjin Medical Journal

基　　金：贵州省教育厅青年科技人才成长项目(黔教合KY字【2018】178);贵州医科大学国家自然科学基金培育项目(19NSP050);。

摘　　要：肿瘤坏死因子相关凋亡诱导配体(TRAIL)可通过特异性识别肿瘤细胞死亡受体而诱导并启动多种凋亡机制,发挥抑制肿瘤的增殖、浸润、转移的作用,但TRAIL对食管癌、胃癌、大肠癌等消化系统恶性肿瘤治疗并不敏感。TRAIL可通过联合使用某些小分子化合物,或通过调节凋亡相关蛋白的表达等来提高其抑癌的能力,然而其具体作用机制尚不清楚。就肿瘤坏死因子相关凋亡诱导配体在消化系统肿瘤治疗中的研究进展进行综述。Tumour necrosis factor-related apoptosis-inducing ligands(TRAIL)can inhibit tumour proliferation,infiltration and metastasis by specifically recognising tumour cell death receptors and inducing and initiating various apoptotic mechanisms.TRAIL is not sensitive to the treatment of digestive malignancies such as oesophageal,gastric and colorectal cancers.TRAIL can improve its anti-cancer ability by combining some small molecular compounds or by regulating the expression of apoptosis-related proteins.However,its exact mechanism of action is not yet clear.This article reviews the research progress of tumor necrosis factor-related apoptosis-inducing ligand in the treatment of digestive system tumors.

关 键 词：消化系统肿瘤 胃肠肿瘤 抗药性 肿瘤 细胞凋亡 TNF相关凋亡诱导配体 

分 类 号：R735[医药卫生—肿瘤]